EBS, I feel unconformable with Yopp's Liver presentations. It has been called here on the board a "data strip-tease" and each time you think you are going to get a kind of interim MOS and you never get it.
OK, the TTS is certainly an indicator of were it goes because normally if your tumour stops progressing your have chances to be stable for a period and survive longer.
Unfortunately you know that many of the patients don't die from their tumours but from the complications/side-effects. SO I would say that in a NORMAL (non-Bavituximab) clinical trial an increase of TTS is of course fine but NO guarantee of a good upcoming MOS because we don't know what OTHER state the patient is in at the moment that his tumour stops progressing.
With Bavituximab we know that, except that it doesn't has side-effects of its own, it intervenes just at that cross-way. It activates the operating system not just for the clean-up of the cancer but also (since the MDSCs are involved) for the combat against inflammations and other collateral damage due to the cancer.
And to answer your question: That is where my expectations are for Liver and the corner from where I expect the news. But after we had AGAIN no MOS (or early interim look into the MOS) I am not at all sure when we are going to get it. MAR would be great but if they want to beat 10.4 then I think MAR will/may not cut it.
If YOPP's presentation would have given the #patients still alive (as they did in the abstract) then we could have adjusted the data. The TTS 6.7 should not go down any more. If that data given to us is correct it is mathematically impossible.
News 
Market Data 
Discover 
